Gilead Sciences, Inc. $GILD Stock Sold by Eurizon Capital SGR S.p.A.

Eurizon Capital SGR S.p.A. lowered its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 3.5% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 832,461 shares of the biopharmaceutical company’s stock after selling 30,056 shares during the period. Eurizon Capital SGR S.p.A. owned about 0.07% of Gilead Sciences worth $124,359,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. PFS Partners LLC increased its position in shares of Gilead Sciences by 101.1% in the third quarter. PFS Partners LLC now owns 191 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 96 shares during the period. Persistent Asset Partners Ltd purchased a new stake in shares of Gilead Sciences during the second quarter worth about $25,000. Laurel Wealth Advisors LLC purchased a new stake in shares of Gilead Sciences during the third quarter worth about $29,000. Kimelman & Baird LLC purchased a new stake in shares of Gilead Sciences during the second quarter worth about $25,000. Finally, Toth Financial Advisory Corp boosted its holdings in shares of Gilead Sciences by 85.5% during the third quarter. Toth Financial Advisory Corp now owns 217 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 100 shares during the period. Institutional investors own 83.67% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently issued reports on the company. JPMorgan Chase & Co. raised their target price on Gilead Sciences from $170.00 to $190.00 and gave the stock an “overweight” rating in a research note on Friday, October 30th. TD Cowen upped their price target on Gilead Sciences from $160.00 to $175.00 and gave the company a “buy” rating in a research report on Friday, October 30th. Jefferies Financial Group set a $196.00 price objective on Gilead Sciences in a report on Wednesday, November 4th. Cantor Fitzgerald increased their price objective on Gilead Sciences from $155.00 to $175.00 and gave the stock an “overweight” rating in a report on Friday, October 30th. Finally, Needham & Company LLC set a $175.00 price objective on Gilead Sciences in a research report on Friday, October 30th. Twenty-three analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $171.07.

Gilead Sciences Stock Down 1.0%

Shares of NASDAQ GILD opened at $167.95 on Friday. The company has a current ratio of 1.38, a quick ratio of 1.22 and a debt-to-equity ratio of 1.84. Gilead Sciences, Inc. has a 12 month low of $116.88 and a 12 month high of $176.58. The firm has a market capitalization of $208.31 billion, a PE ratio of -53.15 and a beta of 0.35. The firm has a fifty day simple moving average of $154.76 and a two-hundred day simple moving average of $141.66.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 EPS for the quarter, topping the consensus estimate of $2.19 by $0.36. The firm had revenue of $8.30 billion during the quarter, compared to analysts’ expectations of $7.81 billion. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The company’s quarterly revenue was up 6.8% compared to the same quarter last year. During the same period last year, the company posted $2.47 EPS. Equities analysts expect that Gilead Sciences, Inc. will post -0.98 earnings per share for the current year.

Gilead Sciences Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be paid a $0.82 dividend. This represents a $3.28 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date of this dividend is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio is presently -103.80%.

More Gilead Sciences News

Here’s some of the latest news about GILD:

• Positive Sentiment: Results from the PURPOSE 5 trial showed twice-yearly injectable lenacapavir had better persistence than daily oral HIV-prevention medicines, with no HIV infections reported in the lenacapavir group. The data could strengthen the commercial outlook for Gilead’s prevention portfolio. Article: Gilead Sciences Posts PURPOSE 5 Win As HIV Shot Beats Daily Pills
• Neutral Sentiment: Gilead announced a collaboration with TelevisaUnivision and the Latin GRAMMY Awards to promote HIV-prevention awareness. The initiative may support outreach but does not indicate a direct near-term financial impact. Article: Gilead Brings HIV Prevention to the 27th Annual Latin GRAMMY Awards
• Negative Sentiment: Drug-price negotiations in Washington are cited as a near-term risk for Gilead, as lower prices could pressure revenue. The article does not quantify the potential impact. Article: Lilly, Gilead Face Near-Term Drug Pricing Risks As Washington Turns Up Heat

Insider Buying and Selling

In other Gilead Sciences news, EVP Keeley Cain Wettan sold 3,399 shares of the firm’s stock in a transaction dated Friday, November 6th. The shares were sold at an average price of $164.11, for a total value of $557,809.89. Following the completion of the sale, the executive vice president directly owned 5,360 shares in the company, valued at $879,629.60. This trade represents a 38.81% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Daniel O’Day sold 102,619 shares of the firm’s stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $175.16, for a total transaction of $17,974,744.04. Following the completion of the sale, the chief executive officer owned 551,683 shares of the company’s stock, valued at $96,632,794.28. This trade represents a 15.68% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 242,709 shares of company stock valued at $39,503,427 over the last quarter. 0.30% of the stock is currently owned by insiders.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C. Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.